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Abstract
EoE is a chronic immune/antigen-mediated clinicopathologic condition that has become an 
increasingly important cause of upper gastrointestinal morbidity in adults and children over the 
past 2 decades. It is diagnosed based on symptoms of esophageal dysfunction, the presence of at 
least 15 eosinophils/high-power field in esophageal biopsies, and exclusion of competing causes 
of esophageal eosinophilia, including proton pump inhibitor-responsive esophageal eosinophilia 
(PPI-REE). We review what we have recently learned about the clinical aspects of EoE, 
discussing the clinical, endoscopic, and histologic features of EoE in adults and children. We 
explain the current diagnostic criteria and challenges to diagnosis, including the role of 
gastroesophageal reflux disease and PPI-REE. It is also important to consider the epidemiology of 
EoE (current incidence of 1/10,000 new cases per year and prevalence of 0.5-1/1,000 cases per 
year) and disease progression. We review the main treatment approaches and new treatment 
options; EoE can be treated with topical corticosteroids such as fluticasone and budesonide, or 
dietary strategies, such as amino acid-based formulas, allergy test-directed elimination diets, and 
non-directed empiric elimination diets. Endoscopic dilation has also become an important tool for 
treatment of fibrostenostic complications of EoE. There are number of unresolved issues in EoE, 
including phenotypes, optimal treatment endpoints, the role of maintenance therapy, and treatment 
of refractory EoE. The care of patients with EoE and the study of the disease span many 
disciplines—EoE is ideally managed by a multidisciplinary team of gastroenterologists, allergists, 
pathologists, and dieticians.
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Eosinophilic esophagitis (EoE) has received increasing attention over the past 2 decades.1–3 
It was rarely recognized before the 1990s, when the presence of intraepithelial eosinophils in 
the esophagus was thought primarily to indicate reflux esophagitis.4 Between 1993 and 
1995, however, the disease, as it is currently recognized, was described in 3 seminal 
studies.5–7 Since then, there has been a nearly exponential increase in the number of 
publications related to EoE;8 the first consensus guidelines for EoE were published in 2007,1 
with revisions in 20112 and 2013.3
Definition
EoE is a chronic, immune-mediated clinicopathologic disease.1–3 The following criteria are 
required for diagnosis: symptoms of esophageal dysfunction; eosinophilic inflammation 
localized to the esophagus, with at least 15 eos/high-power field (hpf) in esophageal 
mucosal biopsies; and exclusion of other recognized causes of esophageal eosinophilia, 
including proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE).2, 3 To fulfil 
the last criterion, patients must be placed on PPI therapy prior to confirming the diagnosis of 
EoE—those with esophageal eosinophilia who respond do not have EoE as it is currently 




Children typically present with 1 or more symptoms such as vomiting, regurgitation, nausea, 
epigastric or abdominal pain, chest pain, water brash, globus, or decreased appetite.9 Less-
common symptoms include growth failure and hematemesis. Infants and toddlers are more 
likely to present with difficulty feeding, manifest as gagging, choking, food refusal, and 
vomiting. Dysphagia is not commonly seen until adolescence.10, 11 The evaluation of young 
children is necessarily affected by interpretation and reporting by an observer (the parent or 
caregiver), and symptoms are often non-specific (e.g., poor feeding). Symptom frequency 
and severity can vary substantially among patients, and do not always correlate with the 
degree of esophageal eosinophilia. The presence of systemic symptoms such as fever or 
weight loss should promote evaluation for a disease process other than EoE.
Children with eosinophilic esophagitis have a higher rate of atopy (asthma, eczema, or 
rhinitis) than children without EoE.12 Approximately 30%-50% of children with EoE have 
asthma and 50%-75% have allergic rhinitis, compared to 10% and 30%, respectively, in the 
general pediatric population, and environmental allergies are approximately 50% more 
common in children with EoE.13, 14 Similarly, 10%-20% of children with EoE have 
immunoglobulin (Ig)E-mediated food allergy (urticaria and anaphylaxis) compared to 
1%-5% of children without EoE; more than 50% of patients have another family member 
who has a history of allergy.15
Children who have other inflammatory bowel disorders including celiac disease or Crohn’s 
disease can have eosinophil-predominant esophageal inflammation.2, 16 However, it is not 
appropriate to make a diagnosis of EoE when there is another condition that could account 
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for the histologic changes. In these cases, treatment should be initiated for the presumed 
primary etiology, with monitoring of the esophageal inflammation. If esophageal 
eosinophilia persists after the primary disease is controlled, then in certain cases EoE can be 
diagnosed as an overlapping condition. EoE has been associated with connective tissue 
diseases, so there may be a shared pathogenic mechanism.17 In contrast, EoE can occur in 
children who have other unrelated medical conditions such as trachea-esophageal fistula, 
Down syndrome, Pfeiffer syndrome, VATER syndrome (vertebral, anal, tracheal, 
esophageal, and renal abnormalities), or CHARGE syndrome (coloboma, heart defects, 
atresia of nasal choanae, retardation of growth/development, genital/urinary abnormalities, 
and ear abnormalities or deafness) without sharing an underlying pathophysiology.2
Features in adults
In contrast to children, the most common presentation of EoE in adults is solid food 
dysphagia.18, 19 Depending on the study design, 60%-100% of patients report 
dysphagia.8, 20–24 EoE is now the most common cause of food impaction among patients 
who visit the emergency department, comprising more than 50% of cases;25–27 more than a 
quarter of adults with EoE reported past food impaction.20, 21, 23, 24 When taking a history 
from a patient with suspected EoE, it is important to ask not only if they are having trouble 
swallowing, but also about dietary modification. Many adults with EoE have adapted their 
eating behaviors to minimize symptoms. A patient may not report dysphagia, but will 
recount being the last person at the table to finish meals, chewing food into a mush, 
lubricating foods, drinking copious amounts of water after each bite, swallowing repeatedly 
to push food down, avoiding foods that tend to get stuck, and crushing or avoiding pills.
In addition to dysphagia, other symptoms are observed in adults with EoE. Heartburn may 
be present in 30%-60% of patients with EoE.20, 21, 23 Among adults with PPI-refractory 
reflux symptoms, EoE is the cause in 1%−8%.23, 28–30 Non-cardiac chest pain has been 
reported in 8%−44% of adults with EoE;21, 23 one study found EoE to be the cause in 6% of 
subjects with this symptom.31 Abdominal pain, nausea, vomiting, diarrhea, and weight loss 
are not typically associated with EoE in adults—patients with these features should be 
evaluated for other disorders, including a more diffuse eosinophilic gastrointestinal disorder.
Atopic diseases, such as food allergies, asthma, allergic rhinitis and sinusitis, and atopic 
dermatitis, are also frequent co-morbidities in adult patients with EoE. Although this strong 
association has long been recognized in children with EoE, it was reported more recently in 
20%-80% of adults with EoE, with even higher rates of allergen sensitization upon 
testing. 21, 23, 32–34 Because of this high prevalence of atopic disease, allergists often 
collaborate with gastroenterologists to identify and manage extra-esophageal allergic 
conditions, food allergies, and dietary changes. Allergy referral is appropriate if these 
conditions are detected.2, 3
Endoscopic features in adults and children
There are a number of esophageal structural changes associated with EoE (Figure 1).1, 2, 35 
Fixed esophageal rings are the prototypical finding, but rings can also be transient, called 
felinization. Strictures often develop in patients with EoE as a result of chronic 
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inflammation and fibrosis. In some cases, the esophageal lumen is diffusely narrowed, 
termed small-caliber esophagus. This can be difficult to appreciate during endoscopy, but 
can be detected on a barium esophagram.36 Linear furrows and white plaques or exudates 
are also frequently seen. A more subtle finding is a decrease in the normal vascular pattern 
due to congestion of the mucosa, termed edema. Crêpe-paper mucosa describes the splitting 
of the esophageal mucosa with passage of the scope. Many of these endoscopic findings 
occur together, but are not all seen in every patient with EoE. For example, the esophagus 
may appear normal in 7%−10% of cases,35 and if biopsies are not analyzed, EoE will be 
missed.
Additionally, there are differences in the endoscopic findings between children and 
adults.21, 35 Children more commonly have either a normal-appearing esophagus or findings 
of plaques or edema, whereas adults more commonly have rings and strictures. Dilation is 
uncommonly performed in children.9, 21 These differences in endoscopic presentation by 
age has led to the concept that some features of EoE are directly attributable to inflammation 
(furrows, plaques, edema), while others represent fibrosis (rings, strictures, narrowing) 
resulting from chronic inflammation.18, 19
Endoscopic features of EoE do not identify patients with this disease with high levels of 
sensitivity or specificity, and therefore cannot be used alone to confirm or refute a 
diagnosis.35 However, a new classification system has been validated for describing EoE-
related endoscopic findings and severity.37 It is called the EoE endoscopic reference score 
(EREFS)—the acronym also reflects the major components of the score: exudates, rings, 
edema, furrows, and strictures. The EREFS can be used in reporting endoscopic findings of 
EoE, and might be used as an outcome measure in clinical trials.
Histologic features in children and adults
The histologic changes of EoE are the same in children and adults. There is a prominent 
eosinophilic infiltration of the esophageal epithelium, which can be detected by standard 
hematoxylin and eosin staining (Figure 2).38 At least 15 eosinophils/hpf must be present to 
consider a diagnosis of EoE, in most cases.1–3 Although this threshold was set to increase 
the uniformity of EoE diagnosis,8 it is somewhat arbitrary—clinical judgment is required to 
interpret the significance of borderline counts. Other histopathologic findings that are 
associated with EoE include eosinophilic degranulation, eosinophil micro-abscesses, basal 
layer hyperplasia with concomitant elongation of the rete pegs, dilated intracellular spaces or 
spongiosis, and, if subepithelial tissue is present for analysis, lamina propria fibrosis (Figure 
2). Of note, none of these findings are pathognomonic for EoE, and histopathologic findings 
alone cannot diagnose EoE.
Because biopsies obtained with conventional forceps sample the esophageal epithelium and 
rarely obtain tissue deeper than the lamina propria, most of the histologic characterization of 
EoE is limited to the mucosa. However, rare esophagectomy specimens from patients with 
EoE have shown transmural eosinophilic inflammation.39, 40 These samples corroborate 
findings from endoscopic ultrasound studies reporting a thickened esophageal wall in 
patients with EoE.41, 42
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Although the criteria for diagnosis of EoE seem straightforward, there are a number of 
challenges in diagnosing this disorder. Esophageal eosinophilia is not specific to EoE, so 
other disorders on the differential diagnosis must be considered (Table 1).1–3 Eosinophilic 
gastroenteritis with esophageal involvement should be assessed by analysis of gastric and 
duodenal biopsies. Hypereosinophilic syndrome is a concern when the peripheral blood 
eosinophil count is above 1500×109 cells/L. Many other causes of esophageal eosinophilia 
are relatively uncommon and can be excluded by collecting a thorough clinical history and 
routine lab tests. However, gastroesophageal reflux disease (GERD) and PPI-REE are the 
most frequently encountered competing conditions.
Many symptoms of GERD and EoE overlap. GERD can also cause high levels of infiltration 
of the esophagus by eosinophils,28 making it particularly difficult to distinguish between 
EoE and GERD. The relationship between these conditions may be even more 
complicated.43 GERD and EoE can simply overlap, EoE might cause GERD (because of 
impaired esophageal clearance of physiologic reflux), and GERD could cause EoE (if reflux 
leads to a leaky epithelial barrier, through which antigens induce an allergic response). 
Therefore, although the presence of GERD does not preclude a diagnosis of EoE, it is 
important to determine the contribution of reflux to the symptoms of patients with EoE. 
Unfortunately, pH monitoring has not been shown to distinguish between these 
conditions.44, 45
Over the past several years, PPI-REE has been described.2, 3, 46 In this condition, patients 
suspected of having EoE (based on symptoms, associated endoscopic findings, and ≥ 15 
eosinophils/hpf in esophageal biopsies) undergo clinical and histologic resolution following 
PPI therapy. It is currently not clear if PPI-REE is a subtype of GERD, a variant of EoE, or a 
different condition altogether.
Since the first report of PPI-REE in a case series,47 studies in children and adults have 
shown that 33%−74% of patients with esophageal eosinophilia respond to 
PPIs.30, 44, 46, 48–50 Clinical, endoscopic, and histologic features of EoE and PPI-REE 
overlap—30, 46, 48, 49 they cannot be distinguished by pH monitoring44, 46, 48 and are 
associated with production of similar cytokines and tissue biomarkers.51, 52 PPIs reduce 
secretion of eotaxin 3 (CCL26) in response to T-helper (Th)2 cytokine stimulation in EoE 
cell lines at physiologic levels,53, 54 and appear to restore the barrier function of the 
esophageal mucosa.55 This area of research is developing rapidly; although PPI-REE and 
EoE are now separate disorders, their relationship might eventually be redefined.
Another diagnostic challenge involves proper tissue sampling from the esophagus. Because 
endoscopic features of EoE are not pathognomic, biopsies must be obtained; guidelines 
recommend collecting at least 2–4 biopsies from 2 separate locations in the esophagus 
(distal and mid/proximal). This is because the infiltration of eosinophils is patchy throughout 
the esophagus,20, 39, 56, 57 and PPIs can have different effects, based on the location of 
eosinophilia,58 so it might not be sufficient to collect a biopsy from 1 site.20, 57, 59 On 
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histopathologic analysis, the convention is to report peak, rather than the average, eosinophil 
counts, and also to report the size of the microscope’s high-power field.2, 3, 8, 38, 60
Emerging modalities
Development of more-efficient and less-invasive methods of EoE diagnosis is an active area 
of investigation. Symptom scores and predictive models have been described,21, 61–63 but 
not validated. Techniques such as narrow-band imaging,64 confocal microscopy,65 
multiphoton fluorescence microscopy,66 and tethered capsule endoscopy67 have been 
described but are largely still in experimental phases. Similarly, there is proof of concept 
that nuclear scintigraphy68 and positon emission topography might be used in diagnosis.69 
The functional luminal imaging probe, which measures esophageal compliance, has led to a 
new understanding of changes in the mecahnical properties of the esophagus in patients with 
EoE, as a result of remodeling. This probe is likely to measure esophageal distensibility and 
caliber with greater accuracy than endoscopy.70 Decreased compliance was associated with 
subsequent risk of food impaction,71 so this technique might also be used to assess treatment 
outcomes. The esophageal string test and cytosponge are novel and minimally invasive 
approaches under investigation.72–74
Biomarkers of EoE are also being investigated. Several studies have shown that staining 
biopsies for eosinophil granules,75–77 mast cells,78 or cytokines,77, 79, 80 can specifically 
identify EoE. A recent study validated that levels of major basic protein, eotaxin 3, and mast 
cell tryptase could distinguish patients with EoE from patients with GERD,81 but EoE could 
not be distinguished from PPI-REE.52 Blood and stool biomarkers have been studied, but as 
of yet have no proven utility.80, 82, 83
A particularly exciting new diagonstic technique involves analysis of gene expression 
patterns in esophageal tissues of patients with suspected EoE. The initial description of the 
EoE-associated transcriptome was a major advance;84 changes in expression of a subset of 
94 genes can identify patients with EoE with high levels of sensitivity and specificity.85 
Although additional studies are required to confirm the utility of this test, EoE might one 
day be diagnosed based on genetic rather than clinicopathologic features.
Epidemiology and Natural history
Epidemiology
EoE is a global disease, with large numbers of cases reported in North and South America, 
Western and Eastern Europe, and Australia; fewer cases have been reported in Asia and the 
Middle East, and, as of yet, none in India or Sub-Saharan Africa.86 EoE affects patients of 
any age, though is more common in children and adults under the age of 50 
years.2, 8, 12, 87, 88 Men are affected more commonly than women, consistently in a ratio of 
3–4:1; most patients with EoE have been reported to be White, though EoE is found among 
all races and ethnicities.2,8, 21, 23, 88–91
The incidence of EoE is approximately 1/10,000 new cases/year,11, 89, 92, 93 although some 
investigators believe this to be an underestimate. Incidence has increased steadily over the 
past 1–2 decades in multiple locations.11, 93, 94 This increase in incidence cannot be fully 
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explained by increasing awareness of the condition or higher rates of endoscopies and 
biopsies.21, 89, 95 In a recent analysis of a large administrative database, the prevalence of 
EoE in the United States was estimated to be 0.5-1/1,000 cases/year.88 This is consistent 
with other reports of EoE prevalence in the general population.89, 93, 96–98
It is intriguing to speculate about why the incidence of EoE is increasing so rapidly86— 
these types of changes usually indicate an environmental, rather than a genetic, cause. A 
number of potential risk factors have also been proposed, including the decreased prevalence 
of Helicobacter pylori infection,99 increased use of PPIs,100 and early life exposures, such 
as to antibiotics.101 Additionally, EoE has been found to more common in cold and arid 
climates,102 as well as in rural areas.103 EoE has also been associated with connective tissue 
and autoimmune diseases.17, 104 The hygiene hypothesis, alterations in the esophageal 
microbiome, changes in food sources, addition of antibiotics or fertilizers to plant and 
animal foodstuffs, and plastic or synthetic food packaging have all been proposed as 
causes.105 It is not known whether one or all of these factors, or some unidentified factor, 
accounts for the risk for EoE.
Natural history
Multiple studies have shown that EoE is a chronic disorder—eosinophilic infiltration and 
associated endoscopic features persist.1–3, 9, 12, 13, 21, 24, 106–114 However, there have not 
been any reports of EoE progressing into a more general eosinophilic gastrointestinal 
disorder, hypereosinophilic syndrome, or eosinophilic leukemia. There are also no reports of 
EoE causing neoplasia, but follow-up times are likely not sufficient yet to fully exclude this 
possibility.
EoE might progress from an inflammatory phenotype, characterized by younger age, 
symptoms of failure to thrive, abdominal pain, heartburn, and endoscopic findings of white 
plaques/exudates and mucosal edema, to a fibrostenotic phenotype, characterized by older 
age, symptoms of dysphagia and food impaction, and endoscopic findings of esophageal 
rings, strictures, and narrowing. Three recent studies all showed that increasing symptom 
length before diagnosis of EoE (a proxy for persistent eosinophilic inflammation without 
treatment) was strongly associated with increasing development of strictures over 
time.18, 19, 115 These findings provide not only important prognostic information, but 
indicate the need to treat the inflammation associated with EoE.
Treatment
Treatment of EoE is based on its pathogenesis.116 In brief, EoE is believed to be a Th2 cell-
mediated immune response (involving interleukin (IL)4, IL5, and IL13) to food and/or 
environmental allergens. IL5 supports eosinophil differentiation and maturation, and IL5 
and IL13 stimulate the esophageal epithelium to produce eotaxin 3—a potent chemokine 
that recruits eosinophils into the esophagus. Activated eosinophils release multiple factors 
that promote local inflammation and tissue injury, including transforming growth factor β. 
This key mediator of tissue remodeling, including subepithelial fibrosis and epithelial 
proliferation, can also cause smooth muscle dysfunction.117, 118 In addition to eosinophils, 
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other inflammatory cells, including T cells, mast cells, basophils, and natural killer cells, are 
also involved.119–121
There are 3 major treatment approaches to EoE, often referred to as the 3 Ds: drugs, diet, 
and dilation. Drugs and dietary changes target the inflammation associated with EoE 
pathogenesis, whereas dilation treats esophageal remodeling and fibrotic complications. 
Choice of treatment depends on patients’ clinical features, patient and provider preferences, 
local expertise, and costs. In general, drugs and diet are typical first line agents, whereas 
dilation is reserved for patients with esophageal strictures or narrow-caliber esophagus. No 
drugs have been approved by the Food and Drug Administration for treatment of EoE, so all 
medications are used to treat this disorder are off label. However, there are strong data to 
support the use of some pharmacologic agents.
Corticosteroids
Corticosteroids are the only pharmacologic therapy shown to improve the clinical and 
histologic features of eosinophilic esophagitis, and are a mainstay of treatment for children 
and adults with EoE. These drugs have been shown to reduce tissue fibrosis and esophageal 
remodeling in patients with EoE.118, 122
Systemic corticosteroids—Systemic corticosteroids such as prednisone or 
methylprednisolone rapidly resolve esophageal eosinophilia and improve symptoms; this 
class of medications was one of the first to be used in patients with EoE. It became clear, 
however, that after the steroid therapy was tapered, symptoms and esophageal eosinophilia 
recurred rapidly.123 Most experience with systemic steroids has been in children. Because of 
concern over long-term side effects, these medications are reserved for patients with severe 
symptoms or growth failure who require therapy for rapid improvement.
Topical corticosteroids—Because of potential side effects from systemic steroids, 
techniques for delivering corticosteroids topically to the esophagus were developed. A case 
series showed that dispensing fluticasone or beclomethasone from a multi-dose inhaler 
(MDI) directly into the patient’s mouth and having the patient swallow, rather than inhale, 
produced excellent effects.124 Larger observational studies showed that this approach was 
effective in a high proportion of patients,9, 125–128 and a number of randomized controlled 
trials (RCTs) have evaluated these drugs.106–109, 111, 129–133 The best studied medications 
are fluticasone, dispensed from an MDI, and budesonide, administered either as a viscous 
slurry or as a swallowed nebulized vapor.
There have been 3 RCTs of fluticasone vs placebo (1 in children, 1 in adults, and 1 enrolling 
children and young adults),106, 109, 133 1 RCT of fluticasone vs prednisone in children,129 
and 2 RCTs of fluticasone vs esomeprazole in adults.130, 134 In each of the placebo-
controlled trials, patients in the fluticasone group had significant reductions in esophageal 
eosinophil counts compared to the placebo group (Figure 3). Doses for fluticasone typically 
range from 440 to 880 mcg/day in children and 880 to 1760 mcg/day in adults. Findings 
from the 2 most recent fluticasone trials indicate that an initial dose of 1760 mcg/day might 
be optimal for all patient age groups.109, 133
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Most studies of budesonide provided it in a slurry mixed with sucralose, termed oral viscous 
budesonide.128, 135 There have been 2 RCTs of budesonide vs placebo in children,107, 111 1 
RCT of swallowed nebulized budesonide vs placebo in adults,108 and 1 RCT of budesonide 
vs swallowed nebulized budesonide.131 All have shown great efficacy in decreasing or 
normalizing eosinophil counts (Figure 3). The usual dose of budesonide ranges from 1 
mg/day in children to 2 mg/day in adolescents and adults. When the aqueous solution is 
used, 3–5 gm of sucralose are required per 2 mL of aqueous solution to achieve the desired 
thickened consistency. Preliminary results from an RCT showed that an effervescent 
budesonide tablet was also effective compared to placebo.132
When prescribing these medications, it is important to instruct the patients and their families 
in the proper technique to optimize esophageal deposition and minimize pulmonary 
delivery.131 For MDIs, the medication should be administered at end expiration during a 
breath hold. For all topical steroids, administration should be after meals, and patients 
should not eat or drink anything for 30–60 minutes after swallowing the drug.
No study has shown adrenal axis suppression after an 8–12 week course of topical 
steroids,107, 109, 111, 131 and complications caused by systemic steroids (mood changes, 
weight gain, etc) are rarely observed. However, there have been no long term follow-up 
studies of topical corticosteroid use in patients with EoE. Budesonide might have increased 
absorption from the gastrointestinal tract in patients with active inflammation, such as those 
with EoE.136 Additionally, because grapefruit inhibits the CYP3A enzyme pathway 
responsible for the high first-pass effect of budesonide, patients taking this drug should not 
ingest grapefruit or its juice.137 Oral candidiasis is uncommon, but esophageal candidiasis 
was identified in follow-up endoscopies of 15%-20% of patients treated with topical 
steroids.106–109, 111, 129, 131, 132 Patients that develop candidiasis should be treated with 
nystatin or fluconazole. Herpes esophagitis has also been reported as a complication of 
topical steroid treatment of EoE.138
Biologics—Antibodies against IL5 (mepolizumab and reslizumab) have been studied for 
treatment of EoE. These antibodies were initially tested in a case series and a small pilot 
RCT.139, 140 Findings from larger RCTs of both antibodies were recently reported. Despite 
encouraging histologic improvements, the clinical response was disappointing compared to 
placebo.110, 112 Because of these mixed results, further studies are in progress.
Omalizumab, an antibody against IgE that is used to treat allergic asthma and chronic 
urticaria, has been examined in 1 RCT of EoE. There were no differences in outcomes of 
patients given the omalizumab or placebo.141 Infliximab, an antibody against tumor necrosis 
factor, was tested in 3 patients and not found to produce a consistent effect.142 Neither of 
these medications are recommended for treatment of EoE.
Leukotriene antagonists and mast cell stabilizers—The data on montelukast are 
mixed. In an initial case series, high doses (in the 20–40 mg range) appeared to be clinically 
effective,143 but follow-up studies in adults and children have not confirmed this 
finding.144, 145 Similarly, cromolyn does not appear to provide any benefit to patients.9 
Therefore, these medications are not recommended for treatment in routine practice.
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Immunomodulators—A case series reported treatment of 3 patients with the 
immunomodulators 6MP or azathioprine.146 Although patients appeared to respond to these 
medications, the disease flared after patients stopped taking them, and then improved again 
after patients restarted them. However, there are no corroborating data to support these 
observations. Because of the potential toxicity of these agents, further experience is required 
before immunomodulators can be recommended for EoE.
Emerging pharmacologic therapies—Our increased understanding of the pathogenesis 
of EoE has identified several other therapeutic targets,116 increasing candidate 
pharmacologic approaches.147 OCT000459 is an oral agent that blocks the effects of 
prostaglandin D2. In a small RCT, its use was associated with a mild, but significant 
decrease in eosinophil count, compared to placebo.148 This agent is available for research 
purposes only. A number of new biologic agents, including monoclonal antibodies against 
IL13, IL4, and eotaxin 3, are under investigation but not yet available for use. Because 
angiotensin receptor blockers are thought to inhibit transforming growth factor β, an early-
phase study is planned to investigate whether this drug is effective against EoE. Finally, new 
topical steroid formulations, including a viscous budesonide suspension and a dissolving 
fluticasone tablet, are being tested.
Dietary therapy
The identification and removal of allergic dietary antigens is also a mainstay of treatment for 
EoE. Although corticosteroids may temporarily improve symptoms, when they are 
discontinued, the disease returns. In contrast, when foods that induce symptoms are 
eliminated from the diet, patients undergo long-term remission without medication. Dietary 
therapy has also been shown to improve esophageal fibrosis and remodeling.122
Dietary approaches to treat EoE include elemental diets with an amino acid-based complete 
liquid formulation,9, 149 directed elimination diets based on allergy test results,150 and non-
directed elimination diets (in which common food antigens are empirically excluded from 
the diet).151 A recent meta-analysis of studies of adults revealed that elemental diets were 
effective for 91% of patients, non-directed diets for 72%, and allergy test-directed diets for 
46%.152 The type of diet selected should be tailored to the needs of the patient and depends 
on the presence or lack of anaphylactic food allergies, the age of the patient, and the 
acceptance of the diet by the patient or family. Furthermore, patients should be referred to a 
dietician with experience treating patients with EoE, to ensure adequate nutrition and 
maximize compliance.
Amino acid-based formulas—Strict elemental diets have been reported to induce 
remission in 88%-96% of children with EoE9, 149, 151 and 72% of adults.153 These 
outcomes, which are better than those from dietary or medical interventions, were achieved 
without any reported complications. Disadvantages of this approach are palatability, a need 
for enteral feeding tubes for some patients, and patient compliance. Elemental formulas are 
expensive and not always covered by traditional insurance plans, so they can pose a 
significant financial burden. Although a strict diet of an amino acid-based formula can 
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initially be difficult for patients (and parents) to accept, there is rapid symptom 
improvement, so the benefits may outweigh the risks of other treatments.
Once histologic remission is established, based on a repeat endoscopic evaluation after 
patients have been on elemental diets for 4–6 weeks, foods are reintroduced. The least 
allergenic foods (vegetable or fruit groups) should be tried first, followed by foods that are 
more likely to cause a response, such as grains, meats, nuts, fish, shellfish, soy, and dairy.149 
A chart with foods organized from least to most allergenic (A to D) can be used to help 
guide food reintroduction, and single foods from a specific food group can be reintroduced 
in the diet every 5–7 days (Figure 4).154 If symptoms do not recur after reintroduction of 
food(s) from 1 group, endoscopy and biopsy are performed 2–3 months later, to provide 
histologic evidence for remission before the next single food from the next food group is 
introduced. However if patients develop symptoms following ingestion of any specific food, 
that food is excluded from the diet and the patient proceeds to the next food in that group, 
once their symptoms have resolved.
Directed elimination diets based on results of allergy testing—Children treated 
with elimination diets based only on results from radio-allergosorbent and/or skin prick tests 
(SPTs) have not been found to induce clinical and histological remission.125 The same was 
true for adults; rates of response were low and the predictive value of the SPT in identifying 
foods that cause symptoms ranged from only 13% to 22%.155, 156 However, when children 
were evaluated by the SPT and atopy patch test (APT), and then placed on elimination diets 
based on the combination of results, 78% had significant clinical and histological 
remission.150 Soy, wheat, chicken, and beef were the foods most frequently identified by the 
APT and SPT. Interestingly, although dairy often produced negative test results, it was the 
most commonly identified inducer of EoE. Most allergists therefore restrict dairy from the 
diet without a test. The APT has not been standarized for food allergies, and is not 
universally available, so it cannot be recommended for all children with EoE.157 Children 
and adults who seek a directed elimination diet require referral to an allergist with 
knowledge of EoE.
Non-directed (empiric) elimination diet—The advantage of a non-directed elimination 
diet is that it does not require allergy testing. This approach was first used to study the 
effects of a 6-food elimination diet in 35 children.151 Cow’s milk protein, soy, wheat, egg, 
peanut/tree nut, and fish/shellfish were the only foods excluded; 74% of subjects made 
significant clinical and histological improvements. This treatment approach has since been 
validated by 2 additional prospective studies in adults. In these studies, 70% to 73% of 
subjects had histological improvements;155, 156 there have been comparable results from 
retrospective studies.158
Once clinical and histological remission is achieved in patients on 6-food elimination diets, 
single food groups can be reintroduced. Patients are evaluated by endoscopy and biopsy 4–6 
weeks after each new food is introduced. The next food is reintroduced after the histology 
examination establishes remission.159
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The primary advantage of the empiric elimination diet over an elemental formula is that it 
allows patients to eat a variety of foods, including meats, grains, fruits, vegetables, and 
legumes. In situations where allergy testing is not easily accessible, and where an elemental 
diet is not a consideration, the empiric diet is the dietary treatment of choice, and may not be 
a significant financial burden. However, there can be a significant endoscopic burden to the 
food re-introduction process, depending on the number of repeat endoscopies needed. As 
many as 10 endoscopic examinations have been required, over the course of 12–18 months, 
in some strict protocols.156 Therefore, the efficacy of empiric diets requiring elimination of 
fewer food groups is also under investigation.160
Dilation
Esophageal dilation of patients with EoE was initially associated with complications— 
perforation rates were as high as 8% and many patients developed deep mucosal tears and 
underwent hospitalization for post-procedural chest pain.161–163 The 2007 Guidelines for 
EoE therefore took a cautious approach, with dilation to be considered only after drug or 
dietary therapy.1 Since that time, however, it has been shown that dilation can be performed 
safely in patients with EoE, and that it can improve symptoms.164–168 A recent meta-
analysis calculated the risk of perforation from EoE to be 0.3%169—similar to the rate of 
dilation in patients without EoE.170
Although dilation has become an acceptable treatment strategy in recent EoE Guidelines,2, 3 
it does not affect the eosinophil-induced inflammation that causes the disease.166 Also, the 
safety data on which the Guidelines are based were collected from expert centers that are 
familiar with dilation therapy for EoE. It is not clear whether low-volume centers have the 
same safety profiles.
Wire-guided bougie, through-the-scope balloons, and non-wire guided bougies have all been 
reported to be effective dilation techniques.165, 171, 172 There have been no head-to-head 
comparisons of the techniques—the dilator is selected based on the preference of the 
endoscopist. Most published studies used either balloons or wire-guided bougies. The goal 
of the dilation is a mucosal tear, defined as a break in the esophageal mucosa in the area of 
the stricture (Figure 5), which is not considered a complication.
Dilation improves symptoms of dysphagia. In a large multicenter series, almost half of 
patients were symptom free 1 year after a single dilation, and more than 40% remained 
symptom free for 2 years.166 However, after dilation, approximately 75% of patients 
reported chest pain or discomfort, rated as moderate or severe in about 20%. It is therefore 
important to counsel patients to expect post-dilation pain and to manage it with reassurance 
and analgesics as needed. This pain rarely requires emergent evaluation to exclude 
esophageal perforation.
Emerging concepts and unresolved issues
EoE is a dynamic field, and for a recently recognized disease, the pace of knowledge 
acquisition has been astounding. The fact that 3 practice guidelines have been published 
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within the last 6 years illustrates this point. As such, it is understandable that many questions 
remain.
Phenotypes
One question concerns the phenotypes of EoE. Many investigators believe that EoE has 
several phenotypes. Clinical phenotypes and symptoms of EoE can vary between children 
and adults; endoscopic phenotypes can be characterized either by inflammation or 
fibrostenosis. There could also be phenotypes associated with atopic status, sex, or race/
ethnicity. No one knows whether EoE might progress from one phenotype to another, or 
whether the phenotypes are static. The different phenotypes have yet to be fully 
characterized, so it is not clear how disease progression and treatment responses vary among 
phenotypes.
Treatment endpoints and symptom-histology discordance
The ideal treatment endpoint in EoE would be complete resolution of clinical symptoms, 
eosinophilic inflammation, and esophageal remodeling. A stringent treatment outcome 
response such as this, however, might be hard to achieve in practice—significant 
improvement in these areas might be a more realistic goal. Additionally, treatment outcomes 
have varied among clinical trials, with nearly every study having a different threshold of 
histologic response (Figure 3).106–109, 111, 129–134 The most appropriate treatment outcome 
is of clinical, research, and regulatory interest, and multiple studies are underway to help 
define this.
Further complicating the picture is that in some cases of EoE, there is often a dissociation 
between symptomatic and histologic response.173 This dissociation may be explained based 
on the balance of inflammatory and fibrostenotic disease activity. For example, a patient 
with a critical stricture that is dilated can have rapid symptom response, but without dietary 
or pharmacologic therapy will still have marked esophageal eosinophilia. In contrast, a 
patient with a stricture who is treated with steroids or diet may achieve histologic 
normalization, but if the stricture does not improve, symptoms of dysphagia will persist. 
Modification of eating behavior to avoid foods that induce dysphagia may also have a role. 
A combination of these factors could explain results of RCTs of topical steroids or anti-IL5 
agents, in which eosinophil counts significantly decreased in the active compared to the 
placebo group, but symptoms improved in both.109, 111, 112
Maintenance therapy and treatment-refractory patients
When treatment is stopped EoE typically recurs,9, 12, 42 raising questions about whether 
treatment should be continued for all patients. The most recent guidelines recommend 
considering maintenance treatment for all patients with EoE—particularly for those with 
severe or rapidly relapsing symptoms, history of food impaction, strictures that require 
dilation, or history of esophageal perforation.3 If a patient has been successfully treated with 
dietary elimination and food triggers have been identified, ongoing elimination of the dietary 
elements should be used as maintenance therapy. However, there is controversy about 
whether topical steroids should be continued indefinitely, particularly in light of the 
potential side effects and lack of long-term data. An approach where the dose is 
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progressively decreased to the lowest dose that keeps the disease in remission seems 
reasonable until more data are available.
A related question is how to approach treatment-refractory disease. Little has been published 
on this topic,174, 175 but it is clear from RCTs of topical steroids and findings from studies of 
selective dietary therapies (not amino acid-based formulas) that between a quarter and half 
of patients with EoE might not respond.106, 109, 155, 158
The first thing to assess is whether a patient is adhering to the prescribed therapy. If so, it is 
important to determine which component of the disease has failed to respond: symptoms, 
inflammation, or remodeling. If eosinophilia persists, then it would be reasonable to switch 
from steroids to diet, or vice versa, expand an elimination diet or consider elemental 
formula, increase topical steroid doses, or consider systemic steroids. If there is a persistent 
stricture, then dilation is appropriate. Superimposed infection should be excluded. If the 
esophagus is patent, inflammation has resolved, but symptoms persist, other causes should 
be pursued. There has been limited experience with second- or third-line pharmacologic 
agents, or with combination therapies. Overall, approximately 50% of patients refractory to 
initial treatment strategies eventually respond to second or third-line agents,175 but this 
observation highlights the need for more effective therapies for EoE.
Conclusions
EoE is a chronic immune/antigen-mediated clinicopathologic condition that has become an 
increasingly important cause of upper gastrointestinal morbidity in adults and children over 
the past 2 decades. A management algorithm is presented in Figure 6. Diagnosis is based on 
symptoms of esophageal dysfunction, demonstration of ≥15 eosinophils/hpf in esophageal 
biopsies, and exclusion of competing causes of esophageal eosinophilia, including PPI-REE. 
Esophageal eosinophilia in and of itself does not indicate EoE. The mainstays of EoE 
treatment are drugs, diet, and dilation. Topical corticosteroids and dietary elimination are 
each acceptable first line treatment approaches. Esophageal dilation can be used for 
treatment of the fibrostenotic complications of EoE. No drugs have been approved by the 
Food and Drug Administration for treatment of EoE, so pharmacologic agents are prescribed 
off label, increasing costs and barriers to access for patients. Similarly, dietary treatments 
and elemental formulas are rarely covered by insurances.
Approved medications and access to nutritional formulas are key milestones for treatment. 
The care of patients with EoE, and the study of the disease, is multidisciplinary and involves 
gastroenterologists, allergists, pathologists, and dieticians. These teams, working with 
patients and advocacy groups, have made great strides in increasing our understanding this 
disease, and ongoing collaborations hold great promise for the future.
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Endoscopic findings in EoE. (A) Fixed esophageal rings, previously called trachealization. 
Rings can vary in severity from subtle ridges to tight fibrotic bands, and full insufflation of 
the esophagus is required to appreciate their extent. (B) Transient esophageal rings, also 
called felinization. (C) Linear furrows, which are fissures that run parallel to the axis of the 
esophagus and have a train track appearance. (D) White plaques/exudates, which are 
eosinophilic micro-abscesses that can be confused with candidal esophagitis; brushings from 
this patient were negative for candida. (E) Esophageal narrowing with mucosa edema and 
decreased vascularity. Of note, decreased vascularity and mucosal edema are also visible in 
images C, D, G, H, and I, and can be a subtle finding in EoE. (F) A more focal stricture in 
the distal esophagus. Strictures can be located at any location in the esophagus, however. 
(G) Crêpe-paper mucosa, in which there is a mucosal tear with passage of the endoscope in 
a narrowed esophagus. (H) A combination of multiple findings including rings, furrows, 
plaques, narrowing, and decreased vascularity. (I) A combination of several findings 
including rings, deep furrows, plaques, and mucosa edema.
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Histologic findings in EoE (40x images). (A) Mucosal biopsy of the esophagus showing a 
marked eosinophilic infiltrate. Additional findings of note include eosinophil degranulation 
(white asteric), which often indicates eosinophil activation; eosinophil microabscesses, 
defined as clusters of at least 4 eosinophils and superficial layering with sloughing of the 
apical epithelial cells (arrow); and basal cell hyperplasia, frequently occupying 50% or more 
of the epithelium, with spongiosis, a result of dilated intracellular spaces reflecting leaky 
mucosal barrier (black bar). (B) In addition to the eosinophilic infiltrate and degranulation 
(white asterisk), this specimen shows lamina propria fibrosis (black bracket).
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Overview of response rates and treatment outcomes in clinical trials of topical 
corticosteroids for EoE. The histologic response rate for the active (blue bars) and 
comparator (green bars) treatments are shown, for the most stringent outcome measure 
reported for each trial. MDI indicates use of a multi-dose inhaler in all three of the placebo-
controlled fluticasone trials, and in one of the comparative trials.106,109,133 Budesonide 
indicates use of a viscous budesonide suspension or slurry,107,111,131 NEB indicates use of 
swallowed nebulized budesonide,108,131 and BET indicates use of a budesonide 
effervescent 132 The studies listed under the fluticasone RCTs and budesonide RCTs headers 
are all placebo controlled.
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Dietary reintroduction of food allergens (Modified with permission from Dr. Spergel and 
colleagues154).
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Examples of esophageal dilation to treat EoE. (A) A guidewire, which was placed with the 
neonatal scope, is seen coursing through a very tight proximal esophageal stricture prior to 
passing the wire-guided bougie. (B) The desired post-dilation effect with a mucosal tear. (C) 
View through an inflated through-the-scope balloon during a dilation at the gastro-
esophageal junction. The developing mucosal tear is seen in the 7–8 o’clock area. (D) The 
desired post-dilation effect with a mucosal tear.
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Algorithm for diagnosis and treatment of EoE.
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Table 1
Differential Diagnosis of Esophageal Eosinophilia
• Eosinophilic esophagitis
• Gastroesophageal reflux disease






• Vasculitis, pemphigus, connective tissue diseases
• Infections (fungal, viral)
• Graft versus host disease
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